Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy

[1] Norwood J(2017)Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens J Acquir Immune Defic Syndr 76 527-531

[2] Turner M(2020)Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy Clin Infect Dis 71 e471-e477

[3] Bofill C(2020)Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide Int J Infect Dis 92 71-77

[4] Lake JE(2020)Weight gain associated with integrase stand transfer inhibitor use in women Clin Infect Dis 71 593-600

[5] Wu K(2017)Dolutegravir and weight gain: an unexpected bothering side effect? AIDS 31 1499-1500

[6] Bares SH(2020)No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV AIDS 34 109-114

[7] Kuo P(2021)No significant changes in weight and body fat mass in suppressed HIV-infected patients switched to dual combination lamivudine plus dolutegravir or raltegravir AIDS Res Hum Retroviruses 37 204-206

[8] Sun H(2020)Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks AIDS 34 789-790

[9] Chuang Y(2020)Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-infected young adults and adolescents: a 10-year observational study Microorganisms 8 864-1862

[10] Wu P(2020)Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine AIDS 34 1859-102

[1] Norwood J(2017)Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens J Acquir Immune Defic Syndr 76 527-531

[2] Turner M(2020)Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy Clin Infect Dis 71 e471-e477

[3] Bofill C(2020)Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to coformulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide Int J Infect Dis 92 71-77

[4] Lake JE(2020)Weight gain associated with integrase stand transfer inhibitor use in women Clin Infect Dis 71 593-600

[5] Wu K(2017)Dolutegravir and weight gain: an unexpected bothering side effect? AIDS 31 1499-1500

[6] Bares SH(2020)No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV AIDS 34 109-114

[7] Kuo P(2021)No significant changes in weight and body fat mass in suppressed HIV-infected patients switched to dual combination lamivudine plus dolutegravir or raltegravir AIDS Res Hum Retroviruses 37 204-206

[8] Sun H(2020)Switch from tenofovir disoproxil fumarate to raltegravir is not associated with weight gain over 96 weeks AIDS 34 789-790

[9] Chuang Y(2020)Switching to integrase inhibitors unlinked to weight increase in perinatally HIV-infected young adults and adolescents: a 10-year observational study Microorganisms 8 864-1862

[10] Wu P(2020)Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine AIDS 34 1859-102